La Congélation de l'embryon équin (influence des conditions d'incorporation du glycérol)

LYON1-BU Santé (693882101) / SudocSudocFranceF

Les Protocoles de mise en charge immédiate et précoce des implants endo-osseux

NANCY1-SCD Pharmacie-Odontologie (543952101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Un site d'habitat du Néolithique ancien à Vénizel "Le Creulet" (Aisne)

International audienceThis article presents the results of excavation in 2007 and 2009 of an early Neolithic settlement located on the alluvial plain of the river Aisne at Vénizel "Le Creulet" (Picardy, France). The discovery of this site provides additional evidence for a dense pattern of early Neolithic settlement in the part of the Aisne valley between Soissons and Missy-sur-Aisne. A total of nine pits were excavated. Three are lateral pits associated with an incomplete houseplan. The other pits may have belonged to houses whose post-holes have not been preserved. As all these features were found on the edge of the excavated area, the original size of the settlement is unknown. The pit fills produced quite low quantities of finds. The analysis of the flint industry indicates two periods of occupation on the site, the earlier dating to the very end of the Seine basin Linear Pottery sequence and the later to Blicquy/Villeneuve-Saint-Germain. The main distinguishing traits here are blade modules and raw materials. The small amount of pottery evidence is in accord with this chrono-cultural attribution. The faunal data point to consumption mainly of caprines in the earlier occupation, and cattle in the later period. These trends, which are well attested on other sites in the region, fit the dating proposed on the basis of the flint industry. The pits also contained fragments of sandstone macrolithic tools, together with some manufacturing or maintenance flakes. Soil samples from pit fills were analysed for charcoal and carbonised plant remains. Around thirty charcoal fragments were identified (oak, Maloideae, alder, elm), as well as three wheat grain

Un site d'habitat du Néolithique ancien à Vénizel "Le Creulet" (Aisne)

National audienc

Gestion de la jument

absen

Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy

International audiencePurpose: Immunotherapy is an alternative for metastatic melanoma patients resistant to chemotherapy. Natural killer (NK) cells are powerful antileukemia effectors and their role in solid tumors is suspected. NK cell activation is regulated by a balance between activating receptors, which detect stress molecules on tumor cells, and HLA-I specific inhibitory receptors. Here, we studied the phenotype and function of NK cells in stage IV metastatic melanoma patients. Experimental Design: Circulating NK cells from 35 healthy donors and 51 patients were studied: 24 patients before chemotherapy (prechemotherapy), 17 patients 1 month after 1 to 4 lines of chemotherapy (postchemotherapy), and 10 patients analyzed pre-and postchemotherapy. NK functionality was carried out toward 2 primary metastatic melanoma cell lines, analyzed for the expression of NK receptor ligands. Results: NK cells from prechemotherapy patients exhibit an NKp46 dim /NKG2A dim phenotype. In contrast, NK cells from postchemotherapy patients display high expression of NKp46 and NKG2A receptors. Purified NK cells from patients are efficiently activated in response to melanoma cells. Melanoma cells express different level of NKG2D ligands and HLA-I molecules. In agreements with their phenotype, NK cells from pre-and postchemotherapy patients present distinct functional status toward these primary melanoma cells. A dynamic label free assay was used to determine the pathways involved in the lysis of melanoma cells by IL-2-activated NK cells. NKG2D, NCR (natural cytotoxicity receptor), and DNAM-1 are involved in the NK-mediated lysis of melanoma cells. Conclusions: These results provide new arguments and clues to design NK cell-based immunotherapeutic strategies for melanoma patients. Clin Cancer Res; 17(9); 2628-37. Ó2011 AACR